University of Michigan MC

University of Michigan Comprehensive Cancer Center

Get in touch
Jump to a Topic:

Doctors at University of Michigan Comprehensive Cancer Center

Excellence in Care at University of Michigan Cancer Center

Since opening in 1986, the University of Michigan Comprehensive Cancer Center (U-M) has continually appeared on U.S. News & World Report’s annual list of “Best Hospitals.” The National Cancer Institute (NCI) designates this institution as a Comprehensive Cancer Center for maintaining the highest standards of excellence in patient care, education, basic science, clinical research and cancer prevention.

The hospital embraces a multidisciplinary approach, with physicians and scientists collaborating to develop comprehensive diagnoses and treatment plans. This approach is invaluable in the study and treatment of lung cancer.

As such, the hospital established the Multidisciplinary Lung Cancer Clinic. This group works closely with the hospital’s Thoracic Oncology Program, which is charged with the research and treatment of lung cancer and other intrathoracic conditions. Team members include thoracic surgeons, medical and radiation oncologists, pulmonologists, gastroenterologists, radiologists, pathologists and nurses.

Among these professionals is medical oncologist Gregory Kalemkerian, M.D., director of the Multidisciplinary Lung Cancer Clinic and a leading expert in lung cancer, mesothelioma and thymomas.

Multidisciplinary Treatment Options at University of Michigan

The lung cancer clinic performs conventional treatments such as surgery, chemotherapy and radiation therapy. These doctors also utilize aggressive combined-modality therapy treatments, including chemotherapy and radiation therapies and combinations, when possible.

However, this department has a particular specialization in performing emerging and minimally invasive techniques, such as:

  • Stereotactic radiosurgery
  • Radiofrequency ablation
  • Photodynamic therapy
  • Esophageal and airway stenting
  • Video-assisted thoracoscopy (VATS)
  • Biologic therapy (biotherapy and immunotherapy)

Thoracic Oncology Program members regularly collaborate to review and discuss patient cases and develop personalized treatment plans, and the team is encouraged to lead and regularly participate in clinical trials and protocols.

Beyond lung cancer, the hospital’s research efforts continue to grow. All U-M faculty members are required to actively practice in the clinical care of patients and/or collaborate in basic, clinical or population research. In 1997, a nine-story cancer center opened its doors, placing patient care, treatment and research all under one roof, delivering research findings much quicker to patients.

Among all U-M and affiliated locations, there are more than 350 physicians/researchers in 36 departments across nine schools, along with nurses, mid-level providers and support staff, all of whom are grouped into teams based on tumor types.

In 2010 alone, U-M treated 83,649 outpatient visits, while 3,894 cancer patients were admitted to the various university hospitals. The cancer center now ranks first among national academic medical centers in grant funding, with an average of more than $157 million received annually.

Pleural and Peritoneal Mesothelioma Treatment at University of Michigan

The University of Michigan Cancer Center has expertise in pleural and peritoneal mesothelioma, both caused primarily by an exposure to toxic asbestos fibers.

Surgical oncologist Dr. Clifford Suhyun Cho handles cases of peritoneal mesothelioma, which forms first on the lining of the abdomen.

Part of his treatment regime includes hyperthermic intraperitoneal chemotherapy, often called the HIPEC procedure, which is used for different abdominal malignancies.

After a complete cytoreduction of all visible mesothelioma tumor cells, HIPEC involves flushing heated chemotherapy through the abdominal cavity for 90 minutes to kill any microscopic cancer cells that evaded the surgeon.

Kalemkerian handles pleural mesothelioma, which is more common than peritoneal mesothelioma and starts in the lining around the lungs.

He meets regularly with the thoracic surgery team and radiation oncologists on staff to review each case.

Mesothelioma Clinical Trials at University of Michigan Cancer Center

  • A phase II study involving immunotherapy and the combination of Opdivo (nivolumab) and Yervoy (ipilimumab) for a number of rare cancers, including pleural and peritoneal mesothelioma. Individuals in this cancer study will provide tumor tissue saved from a biopsy or surgery that will be banked at the University of Nebraska and used by multiple institutions for research. Mesothelioma is one of many cancers being studied.

Disclaimer: University of Michigan Comprehensive Cancer Center has no professional affiliation with

Stethoscope Icon
Get Help Contacting this Cancer Center

We value your privacy. By submitting, you agree to our privacy policy and disclaimer.

stethoscope icon
Get Help Contacting this Doctor

We value your privacy. By submitting, you agree to our privacy policy and disclaimer.

Free Help Finding a Specialist

Get Help Now Mesothelioma Packet

Learn About Treatment

Get a Free Guide

Qualify for Free Medical Care

See If You Qualify

Senior Content Writer

Tim Povtak is an award-winning writer with more than 30 years of reporting national and international news. His specialty is interviewing top mesothelioma specialists and researchers, reporting the latest news at mesothelioma cancer centers and talking with survivors and caregivers.

Walter Pacheco, Managing Editor at
Edited by

10 Cited Article Sources

The sources on all content featured in The Mesothelioma Center at include medical and scientific studies, peer-reviewed studies and other research documents from reputable organizations.


Did this article help you?

Did this article help you?

Thank you for your feedback. Would you like to speak with a Patient Advocate?

Share this article

Last Modified March 24, 2020

Get Your Free Mesothelioma Guide Chat live with a patient advocate now